Poxviridae (e.g., Smallpox Virus, Avian Pox Virus, Fowlpox Virus, Rabbit Myxoma Virus, Vaccinia Virus, Etc.) Patents (Class 424/232.1)
-
Publication number: 20040002472Abstract: Disclosed and claimed are methods and compositions and kits for the vaccination or immunization of an animal, such as a mammal, advantageously a bovine, involving a prime-boost regimen.Type: ApplicationFiled: February 19, 2003Publication date: January 1, 2004Inventors: Jean-Christophe Francis Audonnet, Laurent Bernard Fischer, Simona Barzu-Le-Roux
-
Publication number: 20030228330Abstract: The present invention provides recombinant poxviruses, such as vaccinia virus, that contain an integrated exogenous sequence, such as a foreign gene, encoding a prodrug converting polypeptide that can convert a prodrug to a drug that prevents virus replication or is otherwise toxic to the virus. The recombinant poxviruses can be suitable for use as vaccines. The invention also provides, among other things, methods of inhibiting virus replication, methods of vaccination and methods of treating vaccinated subjects showing signs or otherwise at risk for of vaccination-induced disease.Type: ApplicationFiled: March 14, 2003Publication date: December 11, 2003Inventors: Falko-Guenter Falkner, Georg Holzer, Sogue Coulibaly, Josef Mayrhofer
-
Publication number: 20030224018Abstract: The invention concerns the use of a virus for the preparation of a medicament for the vaccination, treatment, or protection, of a neonatal or prenatal animal, including a human, wherein the virus is capable of infecting the cells of the neonatal or prenatal animal, including a human, but not capable of being replicated to infectious progeny virus in the neonatal or prenatal animal, including a human. The virus is preferably a Modified Vaccinia Virus Ankara.Type: ApplicationFiled: April 18, 2003Publication date: December 4, 2003Applicant: BAVARIAN NORDIC A/SInventors: Mathias Ackermann, Mark Suter, Hans Peter Hefti, Marco Franchini, Sabine Vollstedt, Paul Chaplin
-
Publication number: 20030215466Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.Type: ApplicationFiled: May 16, 2003Publication date: November 20, 2003Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
-
Publication number: 20030206926Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen. 1 TABLE 1 CEF Hela HaCat 143B BHK Vero CV-1 MVA- 579.73 0.04 0.22 0.00 65.88 2.33 0.00 BN MVA- 796.53 0.15 1.17 0.02 131.22 10.66 0.06 575 MVA- 86.68 124.97 59.09 0.83 87.86 34.97 29.70 HLR MVA- 251.89 27.41 1.28 2.91 702.77 1416.46 4.Type: ApplicationFiled: May 16, 2003Publication date: November 6, 2003Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
-
Patent number: 6641816Abstract: The invention relates to a method for enhancing the specific immune response against an immunogenic compound which comprises administering the immunogenic compound together with a poxvirus recombinant and a vaccinal antigen, which is not a poxvirus. The immunological material may be any biological material useful as a vaccine e.g., a polypeptide characteristic of a pathogenic microorganism or associated with a tumoral disorder, a DNA plasmid encoding a peptide or a polypeptide characteristic of a pathogenic microorganism or a tumor-associated antigen, or an hapten coupled to a carrier molecule. The poxvirus may be a live, attenuated or inactivated virus or a recombinant virus. Recombinant virus may encode a heterologous polypeptide such as chemokines, cytokines or co-immunostimulatory molecules or an homologous polypeptide, which is immunologically cross reactive with the immunogenic polypeptide or peptide.Type: GrantFiled: March 9, 2001Date of Patent: November 4, 2003Assignee: Aventis Pasteur S.A.Inventors: Michel Chevalier, Bernard Meignier, Catherine Moste, Suryaprakash Sambhara
-
Publication number: 20030202988Abstract: The present invention provides an attenuated virus, which is derived from Modified Vaccinia Ankara virus and characterized by the loss of its capability to reproductively replicate in human cell lines. It further describes recombinant viruses derived from this virus and the use of the virus, or its recombinants, as a medicament or vaccine. A method is provided for inducing an immune response in individuals who may be immune-compromised, receiving antiviral therapy, or have a pre-existing immunity to the vaccine virus. In addition, a method is provided for the administration of a therapeutically effective amount of the virus, or its recombinants, in a vaccinia virus prime/vaccinia virus boost innoculation regimen.Type: ApplicationFiled: May 16, 2003Publication date: October 30, 2003Inventors: Paul Chaplin, Paul Howley, Christine Meisinger
-
Patent number: 6635472Abstract: This invention relates to the fields of genetic engineering, virus replication and gene transfer. More specifically, this invention relates to polynucleotide construct, recombinant virus, transposon, and their vectors, wherein an ori derived from a DNA virus capable of replicating in vertebrate cells is inserted into the retrovirus, allowing the retrovirus following the reverse transcription to efficiently replicate as extrachromosomal or episomal DNA without the necessity of integration into the host cell chromosome. Additionally, this invention relates to polynucleotide construct, recombinant virus, transposon, and their vectors replicating episomally without aid of an ori and related elements. Also, this invention encompasses preventive, therapeutic, and diagnostic applications employing said constructs, viruses and vectors.Type: GrantFiled: August 14, 1998Date of Patent: October 21, 2003Assignee: Rubicon Laboratory, Inc.Inventor: Vit Lauermann
-
Publication number: 20030194737Abstract: The Parapox B2L virus envelope protein is used as an adjuvant to enhance a subject's response to an administered antigen. Both antibody and cellular immune responses can be modified. B2L protein is particularly useful as an adjuvant for poorly immunogenic tumor vaccines and subunit vaccines, such as those useful for preventing and/or treating flu, tuberculosis, respiratory syncytial virus, anthrax and HIV.Type: ApplicationFiled: April 15, 2003Publication date: October 16, 2003Inventors: Stephen A. Johnston, Michael J. McGuire
-
Patent number: 6632438Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: GrantFiled: July 26, 2001Date of Patent: October 14, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffmann
-
Patent number: 6620412Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: GrantFiled: September 16, 2002Date of Patent: September 16, 2003Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Patent number: 6605280Abstract: Interleukin-18 binding proteins which are capable of binding IL-18 and/or modulating and/or blocking IL-18 activity are provided. Methods for their isolation and recombinant production, DNAs encoding them, DNA vectors expressing them, vectors useful for their expression in humans and other mammals, antibodies against them are also provided.Type: GrantFiled: October 12, 2000Date of Patent: August 12, 2003Assignee: Yeda Research and Development Company LimitedInventors: Daniela Novick, Charles Dinarello, Menachem Rubinstein, Soo Hyun Kim
-
Publication number: 20030138454Abstract: New methods and reagents for vaccination are described which generate a CD8 T cell immune response against malarial and other antigens such as viral and tumour antigens. Novel vaccination regimes are described which employ a priming composition and a boosting composition, the boosting composition comprising a non-replicating or replication-impaired pox virus vector carrying at least one CD8 T cell epitope which is also present in the priming composition. There is also provided a method of inducing a CD4+ T-cell response against a target antigen, by administering a composition comprising a source of one or more CD4+ T cell epitopes of the target antigen wherein the source of CD4+ epitopes is a non-replicating or replication impaired recombinant poxvirus vector. A method of inducing a combined CD4+ and CD8+ T cell response against a target antigen is also described herein.Type: ApplicationFiled: February 19, 2002Publication date: July 24, 2003Applicant: Oxxon Pharmaccines, Ltd.Inventors: Adrian V. S. Hill, Helen McShane, Sarah C. Gilbert, William Reece, Joerg Schneider
-
Patent number: 6596279Abstract: Attenuated recombinant viruses containing DNA encoding an immunodeficiency virus and/or CTL antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: HIV1gag(+pro)(IIIB), gp120(MN)(+transmembrane), nef(BRU)CTL, pol(IIIB)CTL, ELDKWA or LDKW epitopes, preferably HIV1gag(+pro)(IIIB), gp120(MN) (+transmembrane), two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL etpitopes; or two ELDKWA in gp120 V3 or another region or in gp160. The two (2) nef(BRU)CTL and three (3) pol(IIIB)CTL epitopes are preferably CTL1, CTL2, pol1, pol2 and pol3. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses.Type: GrantFiled: August 14, 1998Date of Patent: July 22, 2003Assignee: Virogenetics CorporationInventors: Enzo Paoletti, James Tartaglia, William I. Cox, Robert Gallo, Genoveffa Franchini
-
Publication number: 20030109483Abstract: A purified Parapoxvirus ovis envelope protein termed “B2L” can be used as a monotherapeutic agent. B2L protein also can be used in screening methods to identify potential therapeutic agents for modulating a subject's immune response to the B2L protein.Type: ApplicationFiled: December 6, 2002Publication date: June 12, 2003Inventors: Delanie Cassell, Jeffrey S. Tepper, Isa Samuels, Nathalie Dubois-Stringfellow
-
Publication number: 20030096417Abstract: The invention relates to a method for immunizing a Felidae against FIV, comprising:Type: ApplicationFiled: May 29, 2002Publication date: May 22, 2003Inventor: Laurent Bernard Fischer
-
Publication number: 20030092145Abstract: A composition for treating or preventing virus-induced infections is described, along with a process of producing the composition and methods of the composition's use. The composition comprises viral pathogen-infected cell or tissue, or malignantly or immunologically aberrant cells or tissues which has been reduced and/or denatured. The preferred composition is administered across a mucosal surface of an animal suffering or about suffer from infection. The composition is administered as preventive or therapeutic vaccine.Type: ApplicationFiled: August 23, 2001Publication date: May 15, 2003Inventors: Vic Jira, Vichai Jirathitikal
-
Publication number: 20030082204Abstract: Attenuated recombinant viruses containing DNA coding for a canine distemper virus antigen or measles M or N antigen, as well as methods and compositions employing the viruses, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The DNA can code for at least one of: canine distemper virus fusion protein, canine distemper virus hemagglutinin glycoprotein, canine distemper nucleocaspid portein, canine distemper matrix protein, measles virus nucleocaspid protein, and measles virus matrix protein. The recombinant viruses and gene products therefrom are useful for eliciting protection against canine distemper virus and/or measles virus, and, the gene products and antibodies elicited thereby are useful in assays. Additionally, DNA from the recombinants is used for probes or for generating PCR primers.Type: ApplicationFiled: September 13, 2001Publication date: May 1, 2003Applicant: Aventis Pasteur.Inventors: Enzo Paoletti, James Tartaglia, Jill Taylor, Russell Gettig
-
Publication number: 20030082210Abstract: Disclosed is a method for quality control of an attenuated varicella live vaccine, which comprises subjecting the genomic DNA of a sample varicella vaccine virus to sequence analysis and confirming that the genomic DNA of the sample varicella vaccine virus conserves the 5,745th G, the 105,356th C, the 105,544th G, the 106,262nd C and the 107,252nd C without suffering mutation, wherein the nucleotide numbers are in accordance with the nucleotide numbering system of the nucleotide sequence of the genomic DNA of the varicella virus Dumas strain of SEQ ID NO: 1.Type: ApplicationFiled: August 15, 2001Publication date: May 1, 2003Inventors: Yasuyuki Gomi, Hiroki Sunamachi, Michiaki Takahashi, Koichi Yamanishi
-
Patent number: 6548068Abstract: The present invention is a composition of recombinant virus which has incorporated into its genome or portion thereof a gene encoding an antigen to a disease causing agent and a recombinant virus which has incorporated into its genome or portion thereof a gene encoding an immunostimulatory molecule(s) for the purpose of stimulating an immune response against the disease causing agent. Methods of treatment of diseases such as cancer and diseases caused by pathogenic microorganisms is provide using the composition.Type: GrantFiled: January 7, 2000Date of Patent: April 15, 2003Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Jeffrey Schlom, Judith Kantor, James W. Hodge
-
Publication number: 20030064077Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: ApplicationFiled: July 26, 2001Publication date: April 3, 2003Applicant: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffman
-
Publication number: 20030026813Abstract: The present invention relates to a stable compacted, compressed or hard tableted injectable composition, including a vaccine composition comprising at least one freeze dried antigenic component and a dissolution aid. A package containing the above injectable composition and method to facilitate immunizing a subject against a disease comprising the steps of first dissolving the compacted, compressed or hard tableted vaccine composition in a package with a diluent to form a vaccine solution, and administering the resulting vaccine solution in an amount effective for immunizing is also provided.Type: ApplicationFiled: February 28, 2001Publication date: February 6, 2003Inventors: Gilad Gallili, Norbert Frydman
-
Publication number: 20030022226Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: ApplicationFiled: September 16, 2002Publication date: January 30, 2003Inventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20030021770Abstract: Recombinant pox viruses capable of expressing an immunogenic fragment of the MUC1 tumor-associated antigen are disclosed. The recombinant viruses can be used as vaccines to prevent the establishment of or treat tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The vaccines can be provided as an admixture comprising: (1) a recombinant pox virus encoding the immunogenic fragment of the MUC1 tumor-associated antigen, and (2) a recombinant pox virus encoding a T-cell co-stimulatory factor. The vaccine admixture can be used, e.g., to prevent establishment of tumors or pre-tumorous cells expressing the MUC1 tumor-associated antigen. The MUC1 specific cytotoxic T-cells can be isolated and expanded and used in a method for treating a host having a tumor expressing MCU1 positive tumor cells.Type: ApplicationFiled: January 25, 2002Publication date: January 30, 2003Applicant: Therion Biologics CorporationInventors: Jeffrey Schlom, Judith Kantor, Donald Kufe, Dennis Panicali, Linda Gritz
-
Publication number: 20030021769Abstract: The present invention relates to the use of strains of Parapoxvirus ovis as immunotherapeutic agents for immunodeficiencies of an infectious or non-infectious nature, and to the use of strains of Parapoxvirus ovis for treating tumor diseases and viral infections, and diseases which accompany them, and the use of strains of Parapoxvirus ovis for producing medicaments for use in humans and animals.Type: ApplicationFiled: July 11, 2001Publication date: January 30, 2003Inventors: Olaf Weber, Tobias Schlapp, Angela Siegling, Andreas Knorr, Claudia Hirth-Dietrich, Gudrun Theiss
-
Publication number: 20030003112Abstract: What is described is a recombinant vector, such as a virus; for instance, a poxvirus, such as avipox virus, containing foreign DNA from porcine reproductive and respiratory syndrome virus. What are also described are immunological compositions containing the recombinant poxvirus for inducing an immunological response in a host animal to which the immunological composition is administered. Also described are methods of treating or preventing disease caused by porcine reproductive and respiratory syndrome virus by administering the immunological compositions of the invention to an animal in need of treatment or susceptible to infection by porcine reproductive and respiratory syndrome virus.Type: ApplicationFiled: May 21, 2001Publication date: January 2, 2003Inventors: Jean-Christophe Audonnet, Michel Bublot, Jennifer Perez, Philippe Baudu
-
Publication number: 20020176871Abstract: In this application is described a poxvirus naked DNA vaccine which protects animals against poxvirus challenge comprising IMV and EEV nucleic acids from poxvirus. Methods of use of the vaccine and its advantages are described.Type: ApplicationFiled: March 7, 2001Publication date: November 28, 2002Inventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Publication number: 20020155596Abstract: A vaccine including recombinant vaccinia virus (ATCC VR-1354) having an inserted gene for coding glutamic acid decarboxylase is used for preventing type 1 diabetes mellitus. The glutamic acid decarboxylase expressed from the recombinant virus suppresses or tolerizes the autoreactive T cell, and induces immunological tolerance, thus effectively prevents or delays the development of type 1 diabetes mellitus.Type: ApplicationFiled: November 29, 2001Publication date: October 24, 2002Applicant: Korea Greencross CorporationInventors: Ji Won Yoon, Hee-Sook Jun
-
Publication number: 20020131982Abstract: The invention relates to immunogenic complex comprising iscom and/or iscommatrix and mucus targetting molecules for use for preparing vaccines and immune stimulating compositions for oral, nasal, urogenital and/or rectal administration. The immunogenic complex may comprise at least one glycoside and at least one lipid and a) at least one mucus targetting molecule chosen among substances that target lymphatic tissue and induce immune response when administrated locally on mucous membranes; and b) possibly also one passenger antigen chosen among pharmacologically immune active or immune substances that do not easily reach lymphatic tissue through mucous membranes.Type: ApplicationFiled: August 20, 1998Publication date: September 19, 2002Inventors: BROR MOREIN, KARIN LOVGREN BENGTSSON, JILL EKSTROM
-
Patent number: 6451309Abstract: In this application are described vaccinia monoclonal antibodies. Also provided are mixtures of antibodies of the present invention, as well as methods of using individual antibodies or mixtures thereof for the detection, prevention, and/or therapeutical treatment of vaccinia virus infections in vitro and in vivo.Type: GrantFiled: February 9, 2001Date of Patent: September 17, 2002Assignee: The United States of America as represented by the Secretary of the ArmyInventors: Jay W. Hooper, Alan L. Schmaljohn, Connie S. Schmaljohn
-
Patent number: 6440422Abstract: The present invention relates to recombinant vaccinia viruses derived from the modified vaccinia virus Ankara (MVA) and containing and capable of expressing foreign genes which are inserted at the site of a naturally occurring deletion in the MVA genome, and the use of such recombinant MVA viruses for the production of polypeptides, e.g. antigens or therapeutic agents, or viral vectors for gene therapy, and the use of such recombinant MVA viruses encoding antigens as vaccines.Type: GrantFiled: January 2, 1998Date of Patent: August 27, 2002Assignee: GSF-Forschungszentrum fur Umwelt und Gesenudheit GmbHInventors: Gerd Sutter, Marion Ohlmann, Volker Erfle
-
Publication number: 20020110565Abstract: The present invention provides methods of use of recombinant vaccinia virus from which the region encoding the N-terminal 83 or 54 amino acids of the E3L gene product has been deleted, or amino acids at positions 44 and 66 have been mutated. Compositions comprising the recombinant vaccinia virus are also provided.Type: ApplicationFiled: June 22, 2001Publication date: August 15, 2002Inventors: Bertram Jacobs, Teresa A. Brandt
-
Publication number: 20020076418Abstract: The present invention relates to the use, in humans, of inactivated parapoxviruses for the prophylaxis and treatment of diseases which are accompanied by an increased deposition of collagen, with it being possible for both internal organs, such as the liver, and the skin and its appended structures, to be affected. The invention relates, in particular, to liver fibrosis and/or liver cirrhosis consequent upon virus hepatitis, or to ethanol-induced liver diseases and to cystic fibrosis.Type: ApplicationFiled: July 11, 2001Publication date: June 20, 2002Inventors: Claudia Hirth-Dietrich, Tobias Schlapp, Angela Siegling, Andreas Knorr, Olaf Weber, Gudrun Theiss
-
Patent number: 6406702Abstract: A multivalent poultry vaccine is provided having two or more live biological agents or microbial components. Each live biological agent or microbial component is effective in preventing or treating an avian disease, and the multivalent vaccine is safe and effective for immunizing poultry in ovo. Methods are also provided for vaccinating poultry by administering such a multivalent vaccine in ovo.Type: GrantFiled: February 9, 2000Date of Patent: June 18, 2002Assignee: Regents of the University of MinnesotaInventor: Jagdev M. Sharma
-
Publication number: 20020071849Abstract: Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein binds to chemokines in the CXC group.Type: ApplicationFiled: January 15, 2002Publication date: June 13, 2002Applicant: Isis Innovation LimitedInventors: Geoffrey Smith, Aylwin Ng
-
Publication number: 20020064533Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV core antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.Type: ApplicationFiled: June 4, 2001Publication date: May 30, 2002Inventor: Kenneth Murray
-
Patent number: 6379676Abstract: A method for improving the immune response of an animal to a vaccine, comprising: feeding an animal a diet of contamination-resistant feed, and treating said animal with an anti-viral or anti-bacterial vaccine.Type: GrantFiled: March 10, 1999Date of Patent: April 30, 2002Assignee: Anitox CorporationInventor: Kurt E. Richardson
-
Patent number: 6355252Abstract: Use for novel chemokine-binding protein designated A41L, and chemokine-binding fragments thereof, for the treatment of conditions such as inflammation. The A41L protein beinds to chemokines in the CXC group.Type: GrantFiled: November 22, 1999Date of Patent: March 12, 2002Assignee: Isis Innovation Ltd.Inventors: Geoffrey Smith, Aylwin Ng
-
Patent number: 6352695Abstract: Methods and compositions for selectively modifying nucleic acid molecules in biological compositions, including contacting the composition with an inactivating agent having the formula: where each of R1, R2, R3, R4, R6, R7, and R8 is, independently, H or a monovalent hydrocarbon moiety containing between 1 and 4 carbon atoms, inclusive, provided that R1, R2, R3, R4, R6, R7, and R8 cannot all be H; R5 is a divalent hydrocarbon moiety containing between 2 and 4 carbon atoms, inclusive; X is a pharmaceutically acceptable counter-ion; and n is an integer between 2 and 10, inclusive are disclosed.Type: GrantFiled: October 3, 1997Date of Patent: March 5, 2002Assignee: V.I. Technologies, Inc.Inventors: Edward I. Budowsky, Samuel K. Ackerman, Andrei A. Purmal, Clark M. Edson
-
Publication number: 20020018785Abstract: The present invention relates to novel methods for the identification of antigens recognized by cytotoxic T cells (CTLs) and specific for human tumors, cancers, and infected cells, and the use of such antigens in immunogenic compositions or vaccines to induce regression of tumors, cancers, or infections in mammals, including humans. The invention encompasses methods for induction and isolation of cytotoxic T cells specific for human tumors, cancers and infected cells, and for improved selection of genes that encode the target antigens recognized by these specific T cells. The invention also relates to differential display methods that improve resolution of, and that reduce the frequency of false positives of DNA fragments that are differentially expressed in tumorous, cancerous, or infected tissues versus normal tissues. The invention further relates to the engineering of recombinant viruses as expression vectors for tumor, cancer, or infected cell-specific antigens.Type: ApplicationFiled: April 2, 2001Publication date: February 14, 2002Applicant: University of RochesterInventor: Maurice Zauderer
-
Patent number: 6294176Abstract: The present invention provides a recombinant raccoonpox virus comprising a raccoonpox virus viral genome which contains a foreign DNA sequence inserted into a non-essential region within the HindIII “U” genomic region, the HindIII “M” genomic region, or HindIII “N” genomic region of the raccoonpox virus genome. The present invention provides a recombinant raccoonpox virus comprising a raccoonpox virus viral genome which contains a deletion in a raccoonpox virus host range gene of the viral genome. The present invention provides a homology vector for producing a recombinant raccoonpox virus by inserting a foreign DNA sequence into the raccoonpox virus genome. The present invention provides a recombinant raccoonpox virus which is useful as a vaccine in mammalian and avian species.Type: GrantFiled: July 10, 1998Date of Patent: September 25, 2001Assignee: Schering-Plough Veterinary Corp.Inventors: Mark D. Cochran, David E. Junker
-
Patent number: 6287570Abstract: This invention provides a vaccine for protecting swine against influenza virus by administration of an attenuated recombinant vaccinia virus containing inserts of the hemagglutinin (HA) and nucleoprotein (NP) genes of influenza virus, which express the hemagglutinin and nucleoprotein proteins.Type: GrantFiled: November 23, 1998Date of Patent: September 11, 2001Inventor: Patricia L. Foley
-
Patent number: 6267965Abstract: Attenuated recombinant viruses containing DNA encoding an HCMV antigen, as well as methods and compositions employing the viruses, expression products therefrom, and antibodies generated from the viruses or expression products, are disclosed and claimed. The recombinant viruses can be NYVAC or ALVAC recombinant viruses. The recombinant viruses and gene products therefrom and antibodies generated by the viruses and gene products have several preventive, therapeutic and diagnostic uses. The DNA of the recombinant viruses can be used as probes or for generating PCR primers.Type: GrantFiled: May 26, 1998Date of Patent: July 31, 2001Assignee: Virogenetics CorporationInventors: Enzo Paoletti, Steven E. Pincus, William I. Cox, Elizabeth K. Kauffman
-
Patent number: 6265183Abstract: A method is disclosed for producing a modified eukaryotic cytoplasmic DNA virus by direct molecular cloning of a modified DNA molecule comprising a modified cytoplasmic DNA virus genome. The inventive method comprises the steps of (I) modifying under extracellular conditions a DNA molecule comprising a first cytoplasmic DNA virus genome to produce a modified DNA molecule comprising the modified cytoplasmic DNA virus genome; (II) introducing the modified DNA molecule into a first host cell which packages the modified DNA molecule into infectious virions; and (III) recovering from the host cell virions comprised of the modified viral genome. The host cell is infected with a helper virus which is expressed to package the modified viral genome into infectious virions. Examples of packaging a modified poxvirus genome by a helper poxvirus of the same or different genus are described.Type: GrantFiled: December 19, 1994Date of Patent: July 24, 2001Assignee: Baxter AktiengesellschaftInventors: Friedrich Dorner, Friedrich Scheiflinger, Falko Gunter Falkner, Michael Pfleiderer
-
Patent number: 6251403Abstract: This invention provides a recombinant swinepox virus comprising a foreign DNA sequence inserted into the swinepox virus genomic DNA, wherein the foreign DNA sequence is inserted within a HindIII M fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The invention further provides homology vectors, vaccines and methods of immunization.Type: GrantFiled: June 7, 1995Date of Patent: June 26, 2001Assignee: Syntro CorporationInventors: Mark D. Cochran, David E. Junker
-
Patent number: 6241989Abstract: The present invention relates to multivalent recombinant raccoon poxviruses, containing more than one exogenous gene inserted into either the thymidine kinase gene, the hemagglutinin gene, or a combination thereof. Disclosed is the use of the multivalent recombinant raccoon poxviruses as vaccines to immunize felines against subsequent challenge by feline pathogens. Also disclosed is a method of making a a multivalent recombinant raccoon poxvirus by a recombination process involving the construction of an insertion vector into which the exogenous genes are inserted, and flanking the inserted genes are sequences which can recombine into the raccoon poxvirus thymidine kinase gene, or the hemagglutinin gene, or a combination thereof; introducing both the insertion vector containing the exogenous genes, and raccoon poxvirus into susceptible host cells; and selecting the recombinant raccoon poxvirus from the resultant plaques.Type: GrantFiled: November 3, 1995Date of Patent: June 5, 2001Assignees: Cornell Research Foundation, Inc., The United States of America as represented by the Department of Health and Human ServicesInventors: Fred W. Scott, Christopher K. Ngichabe, Liangbiao Hu, Joseph J. Esposito
-
Patent number: 6221361Abstract: This invention provides a recombinant swinepox virus comprising a foreign DNA inserted into a swinepox virus genomic DNA, wherein the foreign DNA is inserted into an EcoRI site within the approximately 3.2 Kb subfragment of the HindIII K fragment of the swinepox virus genomic DNA and is capable of being expressed in a swinepox virus infected host cell. The invention further provides a recombinant swinepox virus designated S-SPV-120, S-SPV-121, S-SPV-122, S-SPV-127, and S-SPV-128. The invention further provides vaccines and methods of immunization of the recombinant swinepox virus.Type: GrantFiled: July 25, 1996Date of Patent: April 24, 2001Assignee: Syntro CorporationInventors: Mark D. Cochran, David E. Junker
-
Patent number: 6217882Abstract: The present invention provides a recombinant swinepox virus vector containing a heterologous nucleotide sequence encoding a protein from a selected pathogen inserted into, or replacing, all or a portion of a swinepox virus gene, which gene is not essential to replication of the virus in a host cell. Also provided is a recombinant SPV vector into which a pseudorabies antigen is inserted within the TK gene, which is useful in diagnostic, therapeutic, and prophylactic compositions.Type: GrantFiled: April 26, 1999Date of Patent: April 17, 2001Assignee: University of Florida Research Foundation, Inc.Inventors: Richard W. Moyer, Eladio Viñuela, E. P. J. Gibbs
-
Patent number: 6214353Abstract: What is described is a recombinant poxvirus, such as vaccinia virus, containing foreign DNA from Plasmodium Merozoite Surface Antigen 1. What is also described is a vaccine containing the recombinant poxvirus for inducing an immunological response in a host animal inoculated with the vaccine.Type: GrantFiled: May 21, 1998Date of Patent: April 10, 2001Assignees: Pasteur Merieux Serums et Vaccins, The University of HawaiiInventors: Enzo Paoletti, Charles de Taisne, Sandra Chang, George Hui, Wasim A. Siddigui
-
Patent number: 6180398Abstract: An immunization strategy to provide protection against disease caused by infection with a paramyxoviridae virus, specifically respiratory syncytial virus (RSV) and parainfluenza virus, is described. A priming intranasal administration of a recombinant virus expressing at least one RSV or PIV protein or immunogenic sequence there first is made to the host followed by a booster administration of at least one purified RSV or PIV protein or immunogenic fragment thereof, which may be adjuvanted with alum. This immunization strategy provides a safe and effective means of controlling RSV and PIV infections. The strategy leads to a stronger protective immune response than other strategies and to the induction of a more balanced Th-1/Th-2 type response than previously attained.Type: GrantFiled: July 12, 1996Date of Patent: January 30, 2001Assignees: Virogeneitics Corporation, Connaught Laboratories LimitedInventors: Michel H. Klein, James Tartaglia, George A. Cates, Mary E. Ewasyshyn